Show simple item record

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

dc.contributor.authorLane, R
dc.contributor.authorWesnes, KA
dc.contributor.authorMcKeith, I
dc.contributor.authorEdgar, C
dc.contributor.authorEmre, M
dc.date.accessioned2021-03-03T17:26:38Z
dc.date.available2021-03-03T17:26:38Z
dc.date.issued2005
dc.identifier.citationWesnes K., McKeith I., Edgar C., Emre M., Lane R., "Benefits of rivastigmine on attention in dementia associated with Parkinson disease", NEUROLOGY, cilt.65, sa.10, ss.1654-1656, 2005
dc.identifier.issn0028-3878
dc.identifier.otherav_49c33b3d-f961-486f-bb30-0af1b0d60338
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/53018
dc.identifier.urihttps://doi.org/10.1212/01.wnl.0000184517.69816.e9
dc.description.abstractIn a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed.
dc.language.isoeng
dc.subjectKLİNİK NEUROLOJİ
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.titleBenefits of rivastigmine on attention in dementia associated with Parkinson disease
dc.typeMakale
dc.relation.journalNEUROLOGY
dc.contributor.department, ,
dc.identifier.volume65
dc.identifier.issue10
dc.identifier.startpage1654
dc.identifier.endpage1656
dc.contributor.firstauthorID176669


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record